Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Quality control

Companies fined for defective syringes behind diabetic death

The Medicines and Healthcare products Regulatory Agency (MHRA), headquarters pictured, prosecuted Fresenius Kabi and Calea UK for supplying defective pre-filled syringes that contributed to the death of diabetic man in Sheffield in November 2010

Source: Wikimedia Commons

The Medicines and Healthcare products Regulatory Agency (pictured) prosecuted Fresenius Kabi and Calea UK for supplying defective syringes that contributed to the death of a diabetic man

Wholesaler Fresenius Kabi and drug manufacturer Calea UK have been fined for supplying defective pre-filled syringes that contributed to the death of diabetic man Neil Judge at the Northern General Hospital in Sheffield in November 2010. The syringes contained no insulin, which led Judge to go into diabetic ketoacidosis, leading to multi-organ failure.

The Medicines and Healthcare products Regulatory Agency (MHRA) prosecuted the companies. Fresenius Kabi was convicted for its role in a “medicinal failure” that a Coroner had earlier ruled was a major contributory factor in Judge’s death. Sheffield Crown Court fined Fresenius Kabi £500,000 and Calea £50,000. The companies were also ordered to pay £5,900 each in costs.

This isn’t the first manufacturing error for Calea. In August 2011, a patient with cystic fibrosis was dosed with tobramycin from syringes specifically prepared for the individual, and each contained three times the daily dose. The overmedication was only spotted when the patient reported a “fizzing sensation”. Fortunately, the patient had no permanent after effects.

According to Alastair Jeffrey, head of enforcement at the MHRA, the two companies, which are ”very closely linked” (they share a site in Runcorn, Cheshire), were equally responsible for the errors, and the onus was on both to produce and supply products that are fit for purpose.

“I hope this case serves as a clear reminder to others, as the MHRA will not hesitate to take enforcement action when serious failings occur,” Jeffrey adds.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068952

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The Medicines and Healthcare products Regulatory Agency (MHRA), headquarters pictured, prosecuted Fresenius Kabi and Calea UK for supplying defective pre-filled syringes that contributed to the death of diabetic man in Sheffield in November 2010

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.